Regeneron Pharmaceuticals Revenue 2010-2022 | REGN
Regeneron Pharmaceuticals annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Regeneron Pharmaceuticals revenue for the quarter ending September 30, 2022 was $2.936B, a 14.96% decline year-over-year.
- Regeneron Pharmaceuticals revenue for the twelve months ending September 30, 2022 was $13.710B, a 1.24% increase year-over-year.
- Regeneron Pharmaceuticals annual revenue for 2021 was $16.072B, a 89.14% increase from 2020.
- Regeneron Pharmaceuticals annual revenue for 2020 was $8.497B, a 29.58% increase from 2019.
- Regeneron Pharmaceuticals annual revenue for 2019 was $6.558B, a 27.44% increase from 2018.
Regeneron Pharmaceuticals Annual Revenue
(Millions of US $) |
| 2021 |
$16,072 |
| 2020 |
$8,497 |
| 2019 |
$6,558 |
| 2018 |
$5,146 |
| 2017 |
$5,872 |
| 2016 |
$4,860 |
| 2015 |
$4,104 |
| 2014 |
$2,820 |
| 2013 |
$2,105 |
| 2012 |
$1,378 |
| 2011 |
$446 |
| 2010 |
$459 |
| 2009 |
$379 |
Regeneron Pharmaceuticals Quarterly Revenue
(Millions of US $) |
| 2022-09-30 |
$2,936 |
| 2022-06-30 |
$2,857 |
| 2022-03-31 |
$2,965 |
| 2021-12-31 |
$4,952 |
| 2021-09-30 |
$3,453 |
| 2021-06-30 |
$5,139 |
| 2021-03-31 |
$2,529 |
| 2020-12-31 |
$2,423 |
| 2020-09-30 |
$2,294 |
| 2020-06-30 |
$1,952 |
| 2020-03-31 |
$1,828 |
| 2019-12-31 |
$1,864 |
| 2019-09-30 |
$1,744 |
| 2019-06-30 |
$1,578 |
| 2019-03-31 |
$1,373 |
| 2018-12-31 |
$363 |
| 2018-09-30 |
$1,664 |
| 2018-06-30 |
$1,608 |
| 2018-03-31 |
$1,512 |
| 2017-12-31 |
$1,582 |
| 2017-09-30 |
$1,501 |
| 2017-06-30 |
$1,470 |
| 2017-03-31 |
$1,319 |
| 2016-12-31 |
$1,227 |
| 2016-09-30 |
$1,220 |
| 2016-06-30 |
$1,213 |
| 2016-03-31 |
$1,201 |
| 2015-12-31 |
$1,098 |
| 2015-09-30 |
$1,137 |
| 2015-06-30 |
$999 |
| 2015-03-31 |
$870 |
| 2014-12-31 |
$802 |
| 2014-09-30 |
$726 |
| 2014-06-30 |
$666 |
| 2014-03-31 |
$626 |
| 2013-12-31 |
$610 |
| 2013-09-30 |
$597 |
| 2013-06-30 |
$458 |
| 2013-03-31 |
$440 |
| 2012-12-31 |
$415 |
| 2012-09-30 |
$428 |
| 2012-06-30 |
$304 |
| 2012-03-31 |
$232 |
| 2011-12-31 |
$123 |
| 2011-09-30 |
$103 |
| 2011-06-30 |
$108 |
| 2011-03-31 |
$112 |
| 2010-12-31 |
$134 |
| 2010-09-30 |
$106 |
| 2010-06-30 |
$116 |
| 2010-03-31 |
$104 |
| 2009-12-31 |
$97 |
| 2009-09-30 |
$117 |
| 2009-06-30 |
$90 |
| 2009-03-31 |
$75 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$85.284B |
$16.072B |
|
Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
|
